Compare XZO & COLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | XZO | COLL |
|---|---|---|
| Founded | 2012 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.5B |
| IPO Year | 2025 | 2015 |
| Metric | XZO | COLL |
|---|---|---|
| Price | $17.28 | $48.77 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | $27.00 | ★ $45.40 |
| AVG Volume (30 Days) | 224.7K | ★ 558.6K |
| Earning Date | 12-10-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | 0.45 | ★ 1.63 |
| Revenue | $183,708,000.00 | ★ $757,067,000.00 |
| Revenue This Year | N/A | $26.35 |
| Revenue Next Year | N/A | $3.67 |
| P/E Ratio | $38.85 | ★ $30.02 |
| Revenue Growth | ★ 302.33 | 26.34 |
| 52 Week Low | $12.92 | $23.23 |
| 52 Week High | $21.75 | $49.09 |
| Indicator | XZO | COLL |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 74.43 |
| Support Level | N/A | $46.81 |
| Resistance Level | N/A | $48.37 |
| Average True Range (ATR) | 0.00 | 1.33 |
| MACD | 0.00 | -0.11 |
| Stochastic Oscillator | 0.00 | 80.06 |
Exzeo Group Inc provides turnkey insurance technology and operations solutions to insurance carriers and their agents based on a proprietary platform of purpose-built software and data analytics applications that are specifically designed for the property and casualty, or P&C, insurance ecosystem. Its Insurance-as-a-Service (IaaS) platform, which it refers to as the Exzeo Platform, currently includes nine configurable software and data analytics applications that are purpose-built to serve insurance companies and other customers in the insurance value chain. Through the Exzeo Platform, the company provides technology-based solutions and services for all operational and administrative activities and functions needed by P&C insurance carriers and their agents.
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Jornay, Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.